Home › Companies › AMPHASTAR PHARMACEUTICALS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and AMPHASTAR PHARMACEUTICALS INC.’s Form 8-K, filed June 4, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 2, 2025: 7 items on AMPHASTAR PHARMACEUTICALS INC.’s Form 8-K, filed June 4, 2025: 3 elected · 4 approved.
Significant dissent: 1 director (29.2% against).
Notable dissent: 1 director (10.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore AMPHASTAR PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are AMPHASTAR PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jack Y. Zhang | 35,324,626 | 2,162,135 | 13,140 | -- | 4,527,192 | 94% | Elected | — |
| Elect Director: Richard Prins | 33,537,101 | 3,949,663 | 13,137 | -- | 4,527,192 | 89% | Elected | — |
| Elect Director: Diane G. Gerst | 26,544,774 | 10,942,687 | 12,440 | -- | 4,527,192 | 71% | Elected | — |
| 2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025 | 41,473,456 | 526,237 | 27,400 | -- | -- | 99% | Approved | — |
| 3. To approve, on an advisory basis, the compensation of the Company's named executive officers | 35,585,000 | 1,815,521 | 99,380 | -- | 4,527,192 | 95% | Approved | — |
| 4. To approve the amendment of the Charter to reflect Delaware law provisions regarding officer exculpation; and | 34,496,144 | 2,910,874 | 92,883 | -- | 4,527,192 | 92% | Approved | — |
| 5. To approve the amendment of the Charter to remove forum selection provision | 37,354,374 | 52,330 | 93,197 | -- | 4,527,192 | 99.9% | Approved | — |
Source: AMPHASTAR PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 4, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
294 asset managers disclosed a vote on at least one AMPHASTAR PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
71% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to serve until the Company's 2028 annual meeting of stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Diane G. Gerst
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Diane G. Gerst”): 26,544,774 for, 10,942,687 against, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified or until such director's earlier death, resignation or removal.”
Support: 71% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 9,697,649 for, 5,226,026 against, 3,844 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,056,719 | 0 | 0 | 0 | For |
| Vanguard | 2,365,209 | 2,112 | 0 | 0 | For |
| Capitol Series Trust | 0 | 1,207,454 | 0 | 0 | Against |
| Fidelity | 882,648 | 1,400 | 0 | 0 | For |
| Dimensional | 0 | 735,338 | 0 | 0 | Against |
| State Street | 1,391 | 680,079 | 0 | 0 | Against |
| Federated Hermes | 585,115 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 0 | 507,571 | 0 | 0 | Against |
| Pacer Funds Trust | 459,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 408,509 | 0 | 0 | 0 | For |
| Charles Schwab | 307,098 | 0 | 0 | 0 | For |
| American Century | 0 | 300,676 | 0 | 0 | Against |
| Royce | 0 | 244,045 | 0 | 0 | Against |
| Invesco | 0 | 225,593 | 0 | 0 | Against |
| Goldman Sachs | 0 | 130,576 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 129,411 | 0 | 0 | Against |
| Equitable | 60,332 | 47,000 | 0 | 0 | Mixed |
| Janus Detroit Street Trust | 0 | 101,278 | 0 | 0 | Against |
| Prudential/PGIM | 34,158 | 65,975 | 0 | 0 | Mixed |
| TIAA | 0 | 94,242 | 0 | 0 | Against |
| World Funds Trust | 90,068 | 0 | 0 | 0 | For |
| Principal | 70 | 85,626 | 0 | 0 | Against |
| Transamerica | 85,019 | 0 | 0 | 0 | For |
| HOTCHKIS & WILEY FUNDS /DE/ | 0 | 78,100 | 0 | 0 | Against |
| Jackson National | 0 | 72,989 | 0 | 0 | Against |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to serve until the Company's 2028 annual meeting of stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Jack Y. Zhang
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jack Y. Zhang”): 35,324,626 for, 2,162,135 against, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified or until such director's earlier death, resignation or removal.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 14,014,153 for, 909,522 against, 3,844 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,056,719 | 0 | 0 | 0 | For |
| Vanguard | 2,367,318 | 3 | 0 | 0 | For |
| Capitol Series Trust | 1,207,454 | 0 | 0 | 0 | For |
| Fidelity | 884,048 | 0 | 0 | 0 | For |
| Dimensional | 0 | 735,338 | 0 | 0 | Against |
| State Street | 681,418 | 52 | 0 | 0 | For |
| Federated Hermes | 585,115 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 507,571 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 459,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 408,509 | 0 | 0 | 0 | For |
| Charles Schwab | 307,098 | 0 | 0 | 0 | For |
| American Century | 300,676 | 0 | 0 | 0 | For |
| Royce | 244,045 | 0 | 0 | 0 | For |
| Invesco | 225,593 | 0 | 0 | 0 | For |
| Goldman Sachs | 114,785 | 15,791 | 0 | 0 | Mixed |
| Columbia Threadneedle | 129,411 | 0 | 0 | 0 | For |
| Equitable | 107,332 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 101,278 | 0 | 0 | 0 | For |
| Prudential/PGIM | 29,300 | 70,833 | 0 | 0 | Mixed |
| TIAA | 94,242 | 0 | 0 | 0 | For |
| World Funds Trust | 90,068 | 0 | 0 | 0 | For |
| Principal | 85,696 | 0 | 0 | 0 | For |
| Transamerica | 85,019 | 0 | 0 | 0 | For |
| HOTCHKIS & WILEY FUNDS /DE/ | 78,100 | 0 | 0 | 0 | For |
| Jackson National | 64,996 | 7,993 | 0 | 0 | Mixed |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to serve until the Company's 2028 annual meeting of stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Richard Prins
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Richard Prins”): 33,537,101 for, 3,949,663 against, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified or until such director's earlier death, resignation or removal.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 13,158,417 for, 1,765,258 against, 3,844 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,056,719 | 0 | 0 | 0 | For |
| Vanguard | 2,367,315 | 6 | 0 | 0 | For |
| Capitol Series Trust | 1,207,454 | 0 | 0 | 0 | For |
| Fidelity | 884,048 | 0 | 0 | 0 | For |
| Dimensional | 0 | 735,338 | 0 | 0 | Against |
| State Street | 2,066 | 679,404 | 0 | 0 | Against |
| Federated Hermes | 585,115 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 507,571 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 459,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 408,509 | 0 | 0 | 0 | For |
| Charles Schwab | 307,098 | 0 | 0 | 0 | For |
| American Century | 300,676 | 0 | 0 | 0 | For |
| Royce | 244,045 | 0 | 0 | 0 | For |
| Invesco | 225,593 | 0 | 0 | 0 | For |
| Goldman Sachs | 114,785 | 15,791 | 0 | 0 | Mixed |
| Columbia Threadneedle | 0 | 129,411 | 0 | 0 | Against |
| Equitable | 60,332 | 47,000 | 0 | 0 | Mixed |
| Janus Detroit Street Trust | 101,278 | 0 | 0 | 0 | For |
| Prudential/PGIM | 63,458 | 36,675 | 0 | 0 | Mixed |
| TIAA | 94,242 | 0 | 0 | 0 | For |
| World Funds Trust | 90,068 | 0 | 0 | 0 | For |
| Principal | 85,696 | 0 | 0 | 0 | For |
| Transamerica | 85,019 | 0 | 0 | 0 | For |
| HOTCHKIS & WILEY FUNDS /DE/ | 78,100 | 0 | 0 | 0 | For |
| Jackson National | 64,996 | 7,993 | 0 | 0 | Mixed |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
92% Approved · of votes cast
Description as filed by funds: To approve the amendment of our Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding officer exculpation; and
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“4. To approve the amendment of the Charter to reflect Delaware law provisions regarding officer exculpation; and”): 34,496,144 for, 2,910,874 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved the amendment to the Charter to reflect Delaware law provisions regarding officer exculpation.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 14,123,921 for, 768,254 against, 35,344 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,056,719 | 0 | 0 | 0 | For |
| Vanguard | 2,365,219 | 2,102 | 0 | 0 | For |
| Capitol Series Trust | 1,207,454 | 0 | 0 | 0 | For |
| Fidelity | 884,048 | 0 | 0 | 0 | For |
| Dimensional | 735,338 | 0 | 0 | 0 | For |
| State Street | 681,189 | 281 | 0 | 0 | For |
| Federated Hermes | 585,115 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 507,571 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 0 | 459,217 | 0 | 0 | Against |
| T. Rowe Price | 408,509 | 0 | 0 | 0 | For |
| Charles Schwab | 307,098 | 0 | 0 | 0 | For |
| American Century | 300,676 | 0 | 0 | 0 | For |
| Royce | 244,045 | 0 | 0 | 0 | For |
| Invesco | 225,593 | 0 | 0 | 0 | For |
| Goldman Sachs | 130,576 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 129,411 | 0 | 0 | 0 | For |
| Equitable | 107,332 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 101,278 | 0 | 0 | 0 | For |
| Prudential/PGIM | 100,133 | 0 | 0 | 0 | For |
| TIAA | 94,242 | 0 | 0 | 0 | For |
| World Funds Trust | 0 | 90,068 | 0 | 0 | Against |
| Principal | 85,626 | 70 | 0 | 0 | For |
| Transamerica | 32,219 | 52,800 | 0 | 0 | Mixed |
| HOTCHKIS & WILEY FUNDS /DE/ | 78,100 | 0 | 0 | 0 | For |
| Jackson National | 72,989 | 0 | 0 | 0 | For |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To approve the amendment of our Amended and Restated Certificate of Incorporation to remove forum selection provision.
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“5. To approve the amendment of the Charter to remove forum selection provision”): 37,354,374 for, 52,330 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 5: To approve the amendment of the Charter to remove forum selection provision;”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 14,892,175 for, 0 against, 35,344 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,056,719 | 0 | 0 | 0 | For |
| Vanguard | 2,367,321 | 0 | 0 | 0 | For |
| Capitol Series Trust | 1,207,454 | 0 | 0 | 0 | For |
| Fidelity | 884,048 | 0 | 0 | 0 | For |
| Dimensional | 735,338 | 0 | 0 | 0 | For |
| State Street | 681,470 | 0 | 0 | 0 | For |
| Federated Hermes | 585,115 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 507,571 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 459,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 408,509 | 0 | 0 | 0 | For |
| Charles Schwab | 307,098 | 0 | 0 | 0 | For |
| American Century | 300,676 | 0 | 0 | 0 | For |
| Royce | 244,045 | 0 | 0 | 0 | For |
| Invesco | 225,593 | 0 | 0 | 0 | For |
| Goldman Sachs | 130,576 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 129,411 | 0 | 0 | 0 | For |
| Equitable | 107,332 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 101,278 | 0 | 0 | 0 | For |
| Prudential/PGIM | 100,133 | 0 | 0 | 0 | For |
| TIAA | 94,242 | 0 | 0 | 0 | For |
| World Funds Trust | 90,068 | 0 | 0 | 0 | For |
| Principal | 85,696 | 0 | 0 | 0 | For |
| Transamerica | 85,019 | 0 | 0 | 0 | For |
| HOTCHKIS & WILEY FUNDS /DE/ | 78,100 | 0 | 0 | 0 | For |
| Jackson National | 72,989 | 0 | 0 | 0 | For |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 11 wordings of this item as funds reported it.
95% Approved · of votes cast
Prior year: 95.4% for (June 3, 2024 meeting) ▼ 0.2 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers;
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“3. To approve, on an advisory basis, the compensation of the Company's named executive officers”): 35,585,000 for, 1,815,521 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on a non-binding basis, the compensation of the Company's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,056,719 | 0 | 0 | 0 | For |
| Vanguard | 2,365,221 | 2,100 | 0 | 0 | For |
| Capitol Series Trust | 1,207,454 | 0 | 0 | 0 | For |
| Fidelity | 884,048 | 0 | 0 | 0 | For |
| Dimensional | 735,338 | 0 | 0 | 0 | For |
| State Street | 681,231 | 239 | 0 | 0 | For |
| Federated Hermes | 585,115 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 0 | 507,571 | 0 | 0 | Against |
| Pacer Funds Trust | 459,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 408,509 | 0 | 0 | 0 | For |
| Charles Schwab | 307,098 | 0 | 0 | 0 | For |
| American Century | 300,676 | 0 | 0 | 0 | For |
| Royce | 244,045 | 0 | 0 | 0 | For |
| Invesco | 225,593 | 0 | 0 | 0 | For |
| Goldman Sachs | 130,576 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 129,411 | 0 | 0 | 0 | For |
| Equitable | 107,332 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 101,278 | 0 | 0 | 0 | For |
| Prudential/PGIM | 100,133 | 0 | 0 | 0 | For |
| TIAA | 94,242 | 0 | 0 | 0 | For |
| World Funds Trust | 90,068 | 0 | 0 | 0 | For |
| Principal | 85,696 | 0 | 0 | 0 | For |
| Transamerica | 85,019 | 0 | 0 | 0 | For |
| HOTCHKIS & WILEY FUNDS /DE/ | 78,100 | 0 | 0 | 0 | For |
| Jackson National | 72,989 | 0 | 0 | 0 | For |
Fund voting reports, all 87 managers: 14,340,340 for, 551,835 against, 35,344 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 1,419,109 | 12,857 | 0 | 0 | For |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1,253,491 | 0 | 0 | 0 | For |
| Epoch Investment Partners, Inc. | 1,221,045 | 0 | 0 | 0 | For |
| BlackRock | 1,136,276 | 19,390 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 963,241 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 809,903 | 0 | 0 | 0 | For |
| Federated Hermes | 585,115 | 0 | 0 | 0 | For |
| T. Rowe Price | 550,675 | 0 | 0 | 0 | For |
| Boston Trust Walden Co | 0 | 495,076 | 0 | 0 | Against |
| Charles Schwab | 329,326 | 0 | 0 | 0 | For |
| American Century | 302,562 | 0 | 0 | 0 | For |
| Boston Partners | 286,027 | 0 | 0 | 0 | For |
| Invesco | 280,970 | 0 | 0 | 0 | For |
| Northern Trust | 261,970 | 0 | 0 | 0 | For |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | 245,250 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 214,470 | 0 | 0 | Against |
| PRINCIPAL GLOBAL INVESTORS | 213,950 | 0 | 0 | 0 | For |
| Goldman Sachs | 211,956 | 0 | 0 | 0 | For |
| Renaissance | 169,445 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 157,825 | 0 | 0 | 0 | For |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | 144,868 | 12,945 | 0 | 0 | Mixed |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 150,932 | 0 | 0 | Against |
| Granite Investment Partners, LLC | 142,402 | 0 | 0 | 0 | For |
| Two Sigma | 138,851 | 0 | 0 | 0 | For |
| Dimensional | 130,748 | 0 | 0 | 0 | For |
Institutional-manager reports, all 231 managers: 12,717,300 for, 1,103,874 against, 44,341 abstained, 375 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99% Approved · of votes cast
Prior year: 98.7% for (June 3, 2024 meeting) ▲ 0.1 pts
Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025;
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025”): 41,473,456 for, 526,237 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 88 asset managers below reported 14,921,287 for, 2,402 against, 3,844 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 4,056,719 | 0 | 0 | 0 | For |
| Vanguard | 2,365,223 | 2,098 | 0 | 0 | For |
| Capitol Series Trust | 1,207,454 | 0 | 0 | 0 | For |
| Fidelity | 884,048 | 0 | 0 | 0 | For |
| Dimensional | 735,338 | 0 | 0 | 0 | For |
| State Street | 681,418 | 52 | 0 | 0 | For |
| Federated Hermes | 585,115 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 507,571 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 459,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 408,509 | 0 | 0 | 0 | For |
| Charles Schwab | 307,098 | 0 | 0 | 0 | For |
| American Century | 300,676 | 0 | 0 | 0 | For |
| Royce | 244,045 | 0 | 0 | 0 | For |
| Invesco | 225,593 | 0 | 0 | 0 | For |
| Goldman Sachs | 130,576 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 129,411 | 0 | 0 | 0 | For |
| Equitable | 107,332 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 101,278 | 0 | 0 | 0 | For |
| Prudential/PGIM | 100,133 | 0 | 0 | 0 | For |
| TIAA | 94,242 | 0 | 0 | 0 | For |
| World Funds Trust | 90,068 | 0 | 0 | 0 | For |
| Principal | 85,696 | 0 | 0 | 0 | For |
| Transamerica | 85,019 | 0 | 0 | 0 | For |
| HOTCHKIS & WILEY FUNDS /DE/ | 78,100 | 0 | 0 | 0 | For |
| Jackson National | 72,989 | 0 | 0 | 0 | For |
Showing the 25 largest of 88 asset managers. All 88 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 47,670,177 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 8.51% |
| 2 | Vanguard | 4.97% |
| 3 | Capitol Series Trust | 2.53% |
| 4 | Fidelity | 1.85% |
| 5 | Dimensional | 1.54% |
| 6 | State Street | 1.43% |
| 7 | Federated Hermes | 1.23% |
| 8 | BOSTON TRUST WALDEN FUNDS | 1.06% |
| 9 | Pacer Funds Trust | 0.96% |
| 10 | T. Rowe Price | 0.86% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | State Street | 3.00% |
| 2 | FULLER & THALER ASSET MANAGEMENT, INC. | 2.63% |
| 3 | Epoch Investment Partners, Inc. | 2.56% |
| 4 | BlackRock | 2.42% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.02% |
| 6 | MARSHALL WACE, LLP | 1.70% |
| 7 | Federated Hermes | 1.23% |
| 8 | T. Rowe Price | 1.16% |
| 9 | Boston Trust Walden Co | 1.04% |
| 10 | Charles Schwab | 0.69% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Jack Y. Zhang | 12,524,153 | 26.27% | Schedule 13G, filed February 7, 2025 |
| Mary Z. Luo | 12,482,416 | 26.18% | Proxy statement (DEF 14A), table as of March 31, 2025 |
| Applied Physics & Chemistry Laboratories, Inc. | 6,827,679 | 14.32% | Proxy statement (DEF 14A), table as of March 31, 2025 |
| BlackRock | 6,147,658 | 12.90% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 2,422,904 | 5.08% | Form 13F, quarter ended March 31, 2025 |
| State Street | 1,604,614 | 3.37% | Form 13F, quarter ended March 31, 2025 |
| Dimensional Fund Advisors | 1,356,360 | 2.85% | Form 13F, quarter ended March 31, 2025 |
| Geode Capital | 955,076 | 2.00% | Form 13F, quarter ended March 31, 2025 |
| Millennium Management | 868,551 | 1.82% | Form 13F, quarter ended March 31, 2025 |
| Northern Trust | 594,437 | 1.25% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 47,670,177 shares outstanding, as reported by AMPHASTAR PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At AMPHASTAR PHARMACEUTICALS INC.'s shareholder meeting held June 2, 2025, in the 2024-2025 proxy season, 294 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 2,213 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers; — AMPHASTAR PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AMPHASTAR PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AMPHASTAR PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
AMPHASTAR PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “AMPHASTAR PHARMACEUTICALS (AMPH) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/amphastar-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.